Vor Bio Secures $75M, Doses First Sjögren’s Patient, Raises Cash to $530M
Vor Bio dosed its first patient in the global Phase 3 Sjögren’s disease trial and expects generalized myasthenia gravis topline data in 1H 2027; it secured a $75 million private placement boosting pro-forma cash to $530.2 million, funding operations into early 2029. Q4 R&D expenses fell to $19.2 million while G&A rose to $16.8 million.
1. Clinical Development Update
In Q1 2026 Vor Bio initiated its global Phase 3 UPSTREAM SjD trial in primary Sjögren’s disease, dosing the first patient within weeks. Enrollment continues in the global UPSTREAM MG trial for generalized myasthenia gravis, with topline results anticipated in the first half of 2027.
2. Cash Position Strengthened
The company closed a $75 million private placement on March 27, 2026, boosting its pro-forma cash, cash equivalents, and marketable securities to $530.2 million as of December 31, 2025, which is projected to fund operations into early 2029.
3. Expense and Income Highlights
R&D expenses in Q4 2025 decreased to $19.2 million from $25.3 million due to lower headcount and reduced spending on legacy programs, while G&A expenses rose to $16.8 million from $6.0 million on higher stock-based compensation and professional services. Net income for the quarter reached $1.72 billion.
4. Board Enhancements
Vor Bio appointed Andrew Levin, M.D., Ph.D., and Wouter Joustra to its board, bringing additional biotech and life-science investment expertise to support its telitacicept development.